|
Vital Health
News main page...
FDA Acts to Restrict Bioidentical Hormones
at Wyeth’s Request
On January 9, 2008, the FDA took action on behalf of the Wyeth Pharmaceuticals to impose harmful restrictions on the compounding and dispensing of natural Bio-identical Hormone Replacement Therapy (BHRT), specifically compounded medicines containing the hormone Estriol. In making this decision, the FDA has made it clear that it supports the wealth of the pharmaceutical industry rather than the health of U.S. women. The bottom line is this: the FDA and Wyeth Pharmaceuticals, the maker of Premarin, are trying to stop bio-identical hormone replacement therapy to eliminate the competition!
The FDA announced that it will "halt" the compounding of hormone treatments that contain Estriol, the common and critical component of many bio-identical ormone therapies (including OstaB3, PytoB, and other compounded Bi-Est formulas) that meet standards that were established by Congress.
If FDA and Wyeth have their way, you will lose access to this vital treatment option. This action affects hundreds of thousands of women!
We need your help! Please help us by: GETTING INVOLVED AND FIGHTING BACK!
We are working to engage Members of Congress to call on FDA to reverse its decision. We need your help to encourage your Representatives and Senators in Congress and to stand up for the rights of women.
To read my letter to the FDA Commissioner please click here.
To send an automated form letter to your representatives in less than 2 minutes, please click here.
Back To Top |